Table 2

Unadjusted outcomes: RR from logistic regression

(1)(2)(3)(4)(5)(6)
Month 4 combined prevalence of four STIs tested by NAAT*Month 8 combined prevalence of four STIs tested by NAAT*Month 12 combined prevalence of four STIs tested by NAAT*Month 12 combined measure for three STIs detected by serology at baseline and month 12Month 12 combined prevalence of four STIs tested by NAAT* men onlyMonth 12 combined prevalence of four STIs tested by NAAT* women only
High-value CCT (95% CI)1.06 (0.74 to 1.38)0.86 (0.60 to 1.12)0.80 (0.54 to 1.06)1.09 (0.76 to 1.43)0.70 (0.34 to 1.07)0.85 (0.55 to 1.15)
Low-value CCT (95% CI)0.97 (0.66 to 1.28)0.80 (0.55 to 1.04)1.05 (0.75 to 1.35)1.03 (0.71 to 1.35)1.25 (0.73 to 1.77)0.94 (0.62 to 1.25)
Number positive246 (11.7%)260 (12.3%)262 (11.7%)232 (10.4%)99 (9.0%)163 (14.3%)
N210521172242224111051137
Number positives by study arm
 Control arm112 (11.6%)133 (13.5%)126 (12.1%)104 (10.0%)47 (9.0%)79 (15.2%)
 High-value CCT70 (12.3%)66 (11.6%)57 (9.7%)64 (11.0%)18 (6.4%)39 (12.9%)
 Low-value CCT64 (11.3%)61 (10.8%)79 (12.8%)64 (10.4%)34 (11.3%)45 (14.2%)
  • Robust SEs in parentheses, clustered at both the household and the subvillage levels.

  • The reference group for the computation of the RRs is the control group.

  • * Chlamydia, gonorrhoea, trichomonas, Mycoplasma genitalium.

  • HIV, herpes simplex virus 2, syphilis.

  • CCT, conditional cash transfer; NAAT, nucleic acid amplification test; STI, sexually transmitted infection.